Kuehn Law, PLLC is investigating whether officers and directors of Travere Therapeutics breached their fiduciary duties through potential self-dealing. This probe could lead to damages and governance reforms benefiting shareholders. Long-term investors are encouraged to contact the law firm to protect their rights, as there may be limited time to act. The investigation highlights concerns about corporate governance and shareholder protection at Travere Therapeutics.
Travere Therapeutics, Inc. is the subject of this legal investigation. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 30, 2026 20:13 WIB: 60 of 100 health-sector US stocks rose, 35 fell. Notable movers include BDX at USD 184.18 with a 1.21% increase and 100% sell order activity, ADPT at USD 29.10 with a 1.15% increase and 100% buy order activity, and PHG at USD 24.49 with a 1.13% decrease and 100% buy order activity.
UBS upgraded Morgan Stanley Direct Lending Fund (MSDL) from Neutral to Buy following strong Q3 2026 net investment income of $40.3 million, beating earnings estimates. The fund declared a fourth-quarter dividend and plans fee cuts in 2027 to boost in...
Roche presented new data on its Alzheimer’s disease portfolio at the CTAD 2026 conference, highlighting advances in both pharmaceuticals and diagnostics. Key updates include Phase Ib/IIa data for trontinemab showing rapid amyloid clearance, the start...
Valneva announced that 94% of participants maintained a strong antibody response five years after a single dose of its chikungunya vaccine IXCHIQ®. The vaccine showed durable immunity across all age groups, including adults over 65, supporting its po...
A large investor, identified by the address 0x7a6, has purchased nearly 6 million Worldcoin (WLD) tokens over about two months, spending roughly $1.865 million. On November 9, this whale added another 2.098 million WLD tokens to their holdings. The a...
NRG Energy announced its financial results for the third quarter of 2026, posting an adjusted earnings per share (EPS) of $4.68 and revenue totaling $9.47 billion. The company uses adjusted EPS as a non-GAAP measure, which is calculated based on adju...
